Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Farmers Insurance
Johnson and Johnson
Fuji
McKinsey
Boehringer Ingelheim
Covington
Accenture
Merck

Generated: July 20, 2018

DrugPatentWatch Database Preview

Loxapine - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for loxapine and what is the scope of loxapine patent protection?

Loxapine
is the generic ingredient in five branded drugs marketed by Galen Uk , Actavis Labs Ut Inc, Elite Labs Inc, Lannett Co Inc, Mylan, and Watson Labs, and is included in eleven NDAs. There are eighteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Loxapine has two hundred and twenty-five patent family members in twenty countries.

There are eight drug master file entries for loxapine. Two suppliers are listed for this compound.
Summary for loxapine
Medical Subject Heading (MeSH) Categories for loxapine
Synonyms for loxapine
13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,9,12,14-heptaene
13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0;{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaene
13-CHLORO-10-(4-METHYLPIPERAZIN-1-YL)-2-OXA-9-AZATRICYCLO[9.4.0.0(3),?]PENTADECA-1(15),3,5,7,9,11,13-HEPTAENE
1977-10-2
2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine
2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine
2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine
2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine
2-Chloro-11-(4-methylpiperazino)dibenz[b,f][1,4]oxazepine
2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)oxazepine
27833-64-3 (succinate)
3785AH
54810-23-0 (mono-hydrochloride)
8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,5]benzoxazepine
8-chloro-6-(4-methylpiperazino)benzo[b][1,4]benzoxazepine;succinic acid
977L102
AB00053735_15
AB00053735_16
AC1L1H3Z
AC1Q3ZWR
Adasuve
Adasuve (TN)
AKOS030526111
API0006785
AZ-004
BDBM22871
BPBio1_000226
BRD-K39915878-036-04-6
BRD-K39915878-036-05-3
BRN 0626753
BSPBio_000204
BSPBio_003479
C07104
C18H18ClN3O
CCG-204805
CHEBI:50841
CHEMBL831
CL 62,362
CL 62362
CL-62362
CL-71,563
CL-71563
CL71,563
Cloxazepine
CS-1105
D02340
D0U5OE
DB00408
Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-
Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-
Dibenzacepin
Dibenzoazepine
DivK1c_006919
DTXSID7023229
EINECS 217-835-3
GTPL205
HF 3170
HF3170
HSDB 3111
HY-17390
Hydrofluoride 3170
KBio1_001863
KBio2_000835
KBio2_003403
KBio2_005971
KBio3_002983
KBioSS_000835
L001085
LER583670J
Lopac0_000720
Lossapina
Lossapina [DCIT]
Loxapac
Loxapac (TN)
Loxapin
Loxapina
Loxapina [INN-Spanish]
Loxapine (USAN/INN)
Loxapine [USAN:BAN:INN]
Loxapine [USAN:INN:BAN]
Loxapinsuccinate
Loxapinum
Loxapinum [INN-Latin]
Loxepine
Loxipine Maleate
Loxitane
Loxitane (TN)
LOXITANE C
Loxitane IM
Loxitane Intramuscular
Loxitane-C Oral Suspension
LS-61562
LW 3170
NCGC00021145-01
NCGC00021145-02
NCGC00021145-03
NCGC00021145-04
NCGC00021145-05
NCGC00021145-06
NCGC00021145-07
NCGC00021145-08
NCGC00022279-03
NCGC00022279-04
NCGC00022279-05
Oxilapine
PDSP1_001058
PDSP2_001042
PL039237
Prestwick0_000132
Prestwick1_000132
Prestwick2_000132
Prestwick3_000132
QTL1_000050
S 805
S-805
SCHEMBL94146
SPBio_001814
SPBio_002143
SpecPlus_000823
Spectrum_000355
Spectrum2_001737
Spectrum3_001830
Spectrum5_001857
Staccato loxapine
SUM 3170
SUM-3170
UNII-LER583670J
W-5098
XJGVXQDUIWGIRW-UHFFFAOYSA-N
ZINC19796158

US Patents and Regulatory Information for loxapine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Elite Labs Inc LOXAPINE SUCCINATE loxapine succinate CAPSULE;ORAL 076868-002 Aug 4, 2005 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Elite Labs Inc LOXAPINE SUCCINATE loxapine succinate CAPSULE;ORAL 076868-001 Aug 4, 2005 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Elite Labs Inc LOXAPINE SUCCINATE loxapine succinate CAPSULE;ORAL 076868-003 Aug 4, 2005 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for loxapine

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,682,716 Delivery of aerosols containing small particles through an inhalation route ➤ Try a Free Trial
6,716,415 Delivery of sedative-hypnotics through an inhalation route ➤ Try a Free Trial
6,716,417 Delivery on nonsteroidal antiinflammatory drugs through an inhalation route ➤ Try a Free Trial
6,737,042 Delivery of drug esters through an inhalation route ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for loxapine

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90040-2 Sweden ➤ Try a Free Trial PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001 20130220
3 Finland ➤ Try a Free Trial
00609 Netherlands ➤ Try a Free Trial PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
0609 Netherlands ➤ Try a Free Trial PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Cerilliant
Express Scripts
Harvard Business School
Chubb
Johnson and Johnson
Chinese Patent Office
Deloitte
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.